MRZM (Marizyme) Retained Earnings: $-170.32 Mil (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MRZM Marizyme Inc MRZM
12 GF Score
Price $0.00
View Full Analysis

What is Marizyme Retained Earnings?

Marizyme MRZM -99.67% 12 Retained Earnings is $-170.32 Mil as of Sep. 2024. GuruFocus rates MRZM with a GF Score™ of 12/100.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Marizyme's retained earnings for the quarter that ended in Sep. 2024 was $-170.32 Mil.

Marizyme's quarterly retained earnings declined from Mar. 2024 ($-157.56 Mil) to Jun. 2024 ($-161.64 Mil) and declined from Jun. 2024 ($-161.64 Mil) to Sep. 2024 ($-170.32 Mil).

Marizyme's annual retained earnings declined from Dec. 2021 ($-47.82 Mil) to Dec. 2022 ($-85.99 Mil) and declined from Dec. 2022 ($-85.99 Mil) to Dec. 2023 ($-155.53 Mil).


Marizyme  (OTCPK:MRZM) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Marizyme Retained Earnings Historical Data

* Premium members only.

The historical data trend for Marizyme's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marizyme Retained Earnings Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.98 -36.83 -47.82 -85.99 -155.53

Marizyme Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -141.57 -155.53 -157.56 -161.64 -170.32
MRZM
12GF Score
Marizyme Inc MRZM
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marizyme Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-170.32 Mil mean?
Marizyme (MRZM) has a Retained Earnings of $-170.32 Mil as of Sep. 2024. Retained earnings is the amount of net income not issued to shareholders. View historical data on Marizyme and its competitors.
Is Marizyme's Retained Earnings too high?
Marizyme's current Retained Earnings is $-170.32 Mil. Overall, Marizyme has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Marizyme's Retained Earnings compare to CNBX and XSNX?
Marizyme's Retained Earnings of $-170.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Marizyme and its competitors. Marizyme's current Retained Earnings is $-170.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marizyme stock overvalued right now?
Marizyme (MRZM) has a current Retained Earnings of $-170.32 Mil. The current Retained Earnings is $-170.32 Mil. Marizyme's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Marizyme (MRZM), the current Retained Earnings is $-170.32 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marizyme Business Description

Address 555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
12GF Score

Get the complete analysis for MRZM

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price